Catégorie : Cannabis therapeutique

The Cannabis sativa Versus Cannabis indica Debate : An Interview with Ethan Russo, Daniele Piomelli , 2015

The Cannabis sativa Versus Cannabis indica Debate : An Interview with Ethan Russo Daniele Piomelli and Ethan B. Russo Cannabis and Cannabinoid Research, 2016, 1, 1, 44-46 https://doi.org/10.1089/can.2015.29003.ebr   Dr. Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Medical Director of PHYTECS, a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system. Previously, from 2003 to 2014, he served as Senior Medical Advisor and study physician to GW Pharmaceuticals for three Phase III clinical trials of Sativex for alleviation of cancer pain unresponsive to optimized opioid treatment and studies of Epidiolex for intractable epilepsy. He has held faculty appointments in [...]

Lire la suite

Cannabis Roots: A Traditional Therapy with Future Potential for Treating Inflammation and Pain, Natasha R. Ryz et al., 2017

Cannabis Roots: A Traditional Therapy with Future Potential for Treating Inflammation and Pain Natasha R. Ryz, David J. Remillard, Ethan B. Russo Cannabis and Cannabinoid Research, 2017, 2, 1, ReviewOpen Access https://doi.org/10.1089/can.2017.0028 Abstract Introduction: The roots of the cannabis plant have a long history of medical use stretching back millennia. However, the therapeutic potential of cannabis roots has been largely ignored in modern times. Discussion: In the first century, Pliny the Elder described in Natural Histories that a decoction of the root in water could be used to relieve stiffness in the joints, gout, and related conditions. By the 17th century, various herbalists were recommending cannabis root [...]

Lire la suite

The Use of Cannabis for Headache Disorders, Bryson C. Lochte et al., 2017

The Use of Cannabis for Headache Disorders Bryson C. Lochte, Alexandre Beletsky, Nebiyou K. Samuel, Igor Grant Cannabis and Cannabinoid Research, 2017, Vol. 2, No 1., 61-71   https://doi.org/10.1089/can.2016.0033 Abstract Headache disorders are common, debilitating, and, in many cases, inadequately managed by existing treatments. Although clinical trials of cannabis for neuropathic pain have shown promising results, there has been limited research on its use, specifically for headache disorders. This review considers historical prescription practices, summarizes the existing reports on the use of cannabis for headache, and examines the preclinical literature exploring the role of exogenous and endogenous cannabinoids to alter headache pathophysiology. Currently, there is not [...]

Lire la suite

Dossier : le Cannabis et la vision, Le Cannabiste.com, 2018

Dossier : le Cannabis et la vision Le Cannabiste.com https://lecannabiste.com/dossier-le-cannabis-et-la-vision/ 4 juillet 2018 jean-pierre Si vous posez la question à des utilisateurs réguliers de Cannabis, la plupart vous répondra que l’usage de cette plante constitue pour eux une source de confort et de bien-être. Pour autant nous savons tous que l’usage du Cannabis n’est pas sans incidence sur le corps humain. Les implications du Cannabis sur l’organisme sont nombreuses et parfois plus complexes qu’il n’y paraît. Dans cet article nous nous allons nous intéresser de plus près à l’état des connaissances et aux événements marquants qui ont émaillé la recherche dans le domaine si particulier, [...]

Lire la suite

Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition, María M Caffarel et al., 2010

Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition María M Caffarel, Clara Andradas, Emilia Mira, Eduardo Pérez-Gómez, Camilla Cerutti, Gema Moreno-Bueno, Juana M Flores, Isabel García-Real, José Palacios, Santos Mañes, Manuel Guzmán, Cristina Sánchez Molecular Cancer, 2010, 9, 196 http://www.molecular-cancer.com/content/9/1/196   Abstract Background : ErbB2-positive breast cancer is characterized by highly aggressive phenotypes and reduced responsiveness to standard therapies. Although specific ErbB2-targeted therapies have been designed, only a small percentage of patients respond to these treatments and most of them eventually relapse. The existence of this population of particularly aggressive and non-responding or relapsing patients urges the search for novel therapies. The purpose of this [...]

Lire la suite

Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders : From Pathogenesis to a Promising Therapeutic Target, Tommaso Cassano et al., 2017

Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders : From Pathogenesis to a Promising Therapeutic Target Tommaso Cassano, Silvio Calcagnini, Lorenzo Pace, Federico De Marco, Adele Romano and Silvana Gaetani Frontiers in Neuroscience, 2017, 11, article 30 DOI : 10.3389/fnins.2017.00030   Abstract : As a consequence of an increasingly aging population, the number of people affected by neurodegenerative disorders,such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, is rapidly increasing. Although the etiology of these diseases has not been completely defined, common molecular mechanisms including neuroinflammation, excitotoxicity and mitochondrial dysfunction have been confirmed and can be targeted therapeutically. Moreover, recent studies have shown that endogenous cannabinoid signaling [...]

Lire la suite

A Molecular Link Between the Active Component of Marijuana and Alzheimer’s Disease Pathology, Lisa M. Eubanks et al., 2006

A Molecular Link Between the Active Component of Marijuana and Alzheimer's Disease Pathology Lisa M. Eubanks, Claude J. Rogers, Albert E. Beuscher IV, George F. Koob, Arthur J. Olson, Tobin J. Dickerson, and Kim D. Janda Molecular Pharmacology, 2006, 3, 6, 773–777. doi:10.1021/mp060066m Abstract : Alzheimer's disease is the leading cause of dementia among the elderly, and with the ever-increasing size of this population, cases of Alzheimer's disease are expected to triple over the next 50 years. Consequently, the development of treatments that slow or halt the disease progression have become imperative to both improve the quality of life for patients as well as reduce [...]

Lire la suite

Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson’s disease, C. García, R.G. Pertwee, J. Fernandez-Ruiz et al., 2011

Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease C. García, C. Palomo-Garo, M. Garcia-Arencibia, J.A. Ramos, R.G. Pertwee, J. Fernandez-Ruiz British Journal of Pharmacology, 2011, 163, 1495-1506. (Themed Issue : Cannabinoids on Biology and Medicine, Part 1) DOI : 10.1111/j.1476-5381.2011.01278.x   Abstract BACKGROUND AND PURPOSE Previous findings have indicated that a cannabinoid, such as Δ9-THCV, which has antioxidant properties and the ability to activate CB2 receptors but to block CB1, might be a promising therapy for alleviating symptoms and delaying neurodegeneration in Parkinson's disease (PD). EXPERIMENTAL APPROACH The ability of Δ9-THCV to reduce motor inhibition and provide neuroprotection was investigated in rats lesioned with [...]

Lire la suite

Biphasic effects of THC in memory and cognition, Edward J. Calabrese and Alberto Rubio-Casillas, 2018

Biphasic effects of THC in memory and cognition Edward J. Calabrese, Alberto Rubio-Casillas European Journal of Clinical Investigation, 2018, 48, e12920. DOI: 10.1111/eci.12920 Abstract : A generally undesired effect of cannabis smoking is a reversible disruption of short-term memory induced by delta-9-tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. However, this paradigm has been recently challenged by a group of scientists who have shown that THC is also able to improve neurological function in old animals when chronically administered at low concentrations. Moreover, recent studies demonstrated that THC paradoxically promotes hippocampal neurogenesis, prevents neurodegenerative processes occurring in animal models of Alzheimer’s disease, protects from inflammationinduced [...]

Lire la suite

A chronic low dose of Δ9 tetrahydrocannabinol (THC) restores cognitive function in old mice, Andras Bilkei-Gorzo et al., 2017

A chronic low dose of Δ9 tetrahydrocannabinol (THC) restores cognitive function in old mice Andras Bilkei-Gorzo, Onder Albayram, Astrid Draffehn, Kerstin Michel, Anastasia Piyanova, Hannah Oppenheimer, Mona Dvir-Ginzberg, Ildiko Rácz, Thomas Ulas, Sophie Imbeault, Itai Bab, Joachim L Schultze & Andreas Zimmer Nature Medicine, 2017, 23, 782-787. DOI : 10.1038/nm.4311 Abstract : The balance between detrimental, pro-aging, often stochastic processes and counteracting homeostatic mechanisms largely determines the progression of aging. There is substantial evidence suggesting that the endocannabinoid system (ECS) is part of the latter system because it modulates the physiological processes underlying aging. The activity of the ECS declines during aging, as CB1 receptor expression [...]

Lire la suite